Systemic Amyloidosis
9
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP)
Hungarian National Systemic Amyloidosis Registry
Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load
Amyloidosis Incidence in High-Risk Cardiac Device Patients
The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis